• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. Mar 1995; 71(3): 587–591.
PMCID: PMC2033628

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Abstract

A phase III randomised study, comparing treatment with fluorouracil, epidoxorubicin and methotrexate (FEMTX) with the best supportive care, was conducted in patients with unresectable or metastatic gastric cancer. During the period from July 1986 to June 1992, 41 patients were randomised to receive FEMTX or best supportive care. MTX was given in a dose of 1500 mg m-2 intravenously (i.v.) followed after 1 h by 5-FU 1500 mg m-2 i.v. on day 1; leucovorin rescue was started after 24 h (30 mg orally every 6 h for 48 h) and epidoxorubicin 60 mg m-2 i.v. was administered on day 15. In addition both groups received tablets containing vitamins A and E. Response rates for FEMTX were as follows: complete response (CR), 19% (4/21); partial response (PR), 10% (2/21); no change (NC), 33% (7/21); and progressive disease (PD), 24% (5/21). Response rates in the control group were: NC, 20% (4/20); and PD, 80% (16/20). Increased pain was observed in one patient in the treated group and in 11 patients in the control group within the first 2 months. WHO grade III/IV toxicity in the chemotherapy group was as follows: nausea/vomiting 40%, diarrhoea 10%, stomatitis 15%, leucopenia 50% and thrombocytopenia 10%. One possible treatment-related death was due to sepsis. The median time to progression in the FEMTX group was 5.4 months [95% confidence interval (CI) 3.1-11.7 months], but only 1.7 months in the control group (95% CI 1.2-2.7 months) (P = 0.0013). Similarly, the FEMTX group displayed significantly (P = 0.0006) prolonged survival compared with the control group, i.e. median survival 12.3 months (95% CI 7.1-15.6 months) vs 3.1 months (95% CI 1.6-4.6 months). In conclusion, FEMTX combined with vitamin A and E is a fairly well-tolerated treatment, giving a response rate of 29% in patients with advanced gastric cancer, and also prolonging patients' survival. It can be used as a reference treatment in testing new investigational combinations.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1018K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Cocconi G. Chemotherapy of advanced gastric carcinoma: to be completely rewritten? Ann Oncol. 1994 Jan;5(1):8–11. [PubMed]
  • Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061–2067. [PubMed]
  • Dupont JB, Jr, Lee JR, Burton GR, Cohn I., Jr Adenocarcinoma of the stomach: review of 1,497 cases. Cancer. 1978 Mar;41(3):941–947. [PubMed]
  • Ellis P, Cunningham D. Management of carcinomas of the upper gastrointestinal tract. BMJ. 1994 Mar 26;308(6932):834–838. [PMC free article] [PubMed]
  • Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev. 1993 Jan;19(1):29–44. [PubMed]
  • Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977 Mar;35(3):292–298. [PMC free article] [PubMed]
  • Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol. 1992 Apr;10(4):541–548. [PubMed]
  • Klein HO, Wickramanayake PD, Dieterle F, Mohr R, Oerkermann H, Gross R. High-dose MTX/5-FU and adriamycin for gastric cancer. Semin Oncol. 1983 Jun;10(2 Suppl 2):29–31. [PubMed]
  • Kohnoe S, Yoshida M, Takahashi I, Emi Y, Maehara Y, Sugimachi K. Epirubicin is equivalent to adriamycin in vitro against many cancer cells but more effective against gastric cancer cells. Anticancer Res. 1992 Mar-Apr;12(2):389–392. [PubMed]
  • Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. [PubMed]
  • Moertel CG. The natural history of advanced gastric cancer. Surg Gynecol Obstet. 1968 May;126(5):1071–1074. [PubMed]
  • Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993 Jul 1;72(1):37–41. [PubMed]
  • Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. [PMC free article] [PubMed]
  • Pyrhönen SO, Kouri MO. Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer. Eur J Cancer. 1992;28A(11):1828–1832. [PubMed]
  • Pyrhönen S, Valtonen M. Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract. Lancet. 1990 Jul 14;336(8707):127–127. [PubMed]
  • Wilke H, Preusser P, Fink U, Achterrath W, Meyer HJ, Stahl M, Lenaz L, Meyer J, Siewert JR, Geerlings H, et al. New developments in the treatment of gastric carcinoma. Semin Oncol. 1990 Feb;17(1 Suppl 2):61–70. [PubMed]
  • Wils JA. Chemotherapy for gastrointestinal cancer: new hopes or new disappointments? Scand J Gastroenterol Suppl. 1992;194:87–94. [PubMed]
  • Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol. 1991 May;9(5):827–831. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...